Orphazyme A/S

Equities

ORPHA

DK0062502894

Biotechnology & Medical Research

Delayed Nasdaq Copenhagen 05:13:16 2024-03-19 am EDT 5-day change 1st Jan Change
1,155 DKK -3.73% Intraday chart for Orphazyme A/S -4.53% -13.14%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
FDA Extends Review of Zevra's Arimoclomol by Three Months DJ
Orphazyme A/S acquired an additional unknown minority stake in CombiGene AB (OM:COMBI). CI
Zevra Therapeutics Refiles Arimoclomol Application With FDA DJ
Orphazyme A/S Provides Earnings Guidance for the Full Year 2023 CI
Orphazyme A/S Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Orphazyme A/S Announces Anders Fink Vadsholt to Step Down as CEO CI
Orphazyme A/S Announces Anders Fink Vadsholt to Step Down as CFO CI
Orphazyme A/S Provides Earnings Guidance for the Full-Year 2023 CI
Orphazyme A/S Announces Board Changes CI
Orphazyme A/S Provides Earnings Guidance for the Full-Year 2023 CI
Orphazyme A/S Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Orphazyme A/S(CPSE:ORPHA) added to OMX Nordic Small Cap Index CI
Orphazyme A/S Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Orphazyme A/S Revises Earnings Guidance for the Year 2022 CI
Orphazyme A/S Announces Board Appointment CI
Orphazyme A/S Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Orphazyme A/S Provides Earnings Guidance for the Full Year of 2022 CI
Orphazyme Closes $18 Million Sale Of Assets, Business Operations Under Restructuring Plan MT
KemPharm Denmark A/S acquired Substantially All Assets and Business Activities of Orphazyme A/S for $18 million. CI
Orphazyme A/S Announces Executive Changes CI
Orphazyme A/S(CPSE:ORPHA) dropped from S&P Global BMI Index CI
KemPharm Agrees to Buy Orphazyme for $12.8 Million MT
KemPharm Denmark A/S agreed to acquire substantially all assets and business activities of Orphazyme A/S for $18 million. CI
Orphazyme's American Depositary Shares Delisted From Nasdaq MT
Orphazyme A/S(OTCPK:ORPH.Y) dropped from NASDAQ Composite Index CI
Chart Orphazyme A/S
More charts
Orphazyme A/S, formerly Orphazyme ApS, is a Denmark-based company active within the biopharmaceutical industry. It develops new therapies for the treatment of a family of genetic disorders. The Company's main focus is on preclinical development of medicines for the treatment of lysosomal storage diseases (LSDs), a group of approximately 50 genetic disorders that result from deficiencies of lysosomal enzymes or other lysosomal components, and protein aggregation diseases. The Company's candidate, arimoclomol, stimulates the production of the cells? protein rescue system, the heat shock proteins, which helps the misfolded proteins to either get back to their functional shape or, if this cannot be achieved, remove them from the cells by means of the cells? recycling system, the lysosomes, so they no longer form toxic aggregates. The Company collaborates with academic institutions in Europe and the United States.
More about the company
  1. Stock
  2. Equities
  3. Stock Orphazyme A/S - Nasdaq Copenhagen
  4. News Orphazyme A/S
  5. Orphazyme A/S : European ADRs Move Higher in Thursday Trading